Merck & Co Newsroom

Merck Stops Lung Cancer Study For Keytruda Combo Due To Ineffective Results, Side Effects

BenzingaAug 8 11:51 ET

Looking Into Merck & Co's Recent Short Interest

BenzingaAug 8 11:30 ET

Merck Ends Trial Evaluating Lung Cancer Treatment Following Committee Recommendation

WSJAug 8 07:38 ET

Merck Halts Phase 3 Trial of Lung Cancer Combination Therapy

MT NewswiresAug 8 07:23 ET

Merck Lung Cancer Combo Therapy Fails in Phase 3 Trial

Seeking AlphaAug 8 07:09 ET

Merck Says It's Discontinuing a Late-stage Trial of a Lung Cancer Treatment After High Number of Adverse Events

MarketWatchAug 8 07:09 ET

Merck to Discontinue Phase 3 Lung Cancer Drug Trial on Committee's Recommendation

MT NewswiresAug 8 06:58 ET

Express News | Merck & Co Inc - Discontinues Phase 3 Keyvibe-008 Trial

ReutersAug 8 06:45 ET

Express News | Merck Provides Update on Phase 3 Keyvibe-008 Trial Evaluating an Investigational Fixed-Dose Combination of Vibostolimab and Pembrolizumab in Patients With Extensive-Stage Small Cell Lung Cancer

ReutersAug 8 06:45 ET

Merck Provides Update on Phase 3 KeyVibe-008 Trial Evaluating an Investigational Fixed-Dose Combination of Vibostolimab and Pembrolizumab in Patients With Extensive-Stage Small Cell Lung Cancer

BusinesswireAug 8 06:45 ET

Guolian Securities: Increased attention to tumor immunology, recommend focusing on targeted drugs such as PD1/IL2 in pharmaceutical companies.

With the increasing attention to tumor immunity, and the successive launch of advantageous products, bullish on PD1/IL2 and PD1/IL15 targeted drugs.

Zhitong FinanceAug 8 02:55 ET

Express News | Merck & Co Inc : Berenberg Cuts Target Price to $135 From $143

ReutersAug 8 00:44 ET

Merck & Co. Stock: Analyst Estimates & Ratings

BarchartAug 7 09:47 ET

Organon Extends Selloff After Q2 Results

Seeking AlphaAug 6 14:27 ET

Merck (NYSE:MRK) Seems To Use Debt Quite Sensibly

Yahoo FinanceAug 6 09:00 ET

Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities

GlobeNewswireAug 6 09:00 ET

Daiwa Securities Adjusts Merck & Company Price Target to $130 From $150, Maintains Outperform Rating

MT NewswiresAug 6 07:29 ET · Ratings

Merck, Daiichi Sankyo Expand Cancer Drug Deal

Seeking AlphaAug 6 07:29 ET

Express News | Daiichi Sankyo Co Ltd - Under Terms of Agreement, Merck Will Receive an Upfront Cash Payment of $170 Mln

ReutersAug 6 06:45 ET

Express News | Daiichi Sankyo and Merck Enter Into Global Development and Commercialization Agreement for Mk-6070

ReutersAug 6 06:45 ET